This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Acer's (ACER) NDA for ACER-001 in UCD Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022. Stock up.
Opexa Therapeutics, Inc. (ACER) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Opexa Therapeutics, Inc. (ACER) delivered earnings and revenue surprises of 36.11% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study
by Zacks Equity Research
Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.
Jazz Pharma (JAZZ) Gets FDA Approval for Leukemia Drug Rylaze
by Zacks Equity Research
Jazz Pharma (JAZZ) gets FDA approval for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics
4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness
by Kinjel Shah
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in the second quarter of 2021. However, with demand trends expected to improve, XNCR, ORGO, CPIX, and ACER may prove to be good additions to one's portfolio.
What Makes Opexa Therapeutics, Inc. (ACER) a New Buy Stock
by Zacks Equity Research
Opexa Therapeutics, Inc. (ACER) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Sell Stocks for September 3rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Factors Setting the Tone for Deere (DE) in Q3 Earnings
by Zacks Equity Research
Replacement demand for agricultural equipment and strong demand in construction likely to be conducive to Deere's (DE) third-quarter fiscal 2019 results.
Can Pharmacy Services Drive CVS Health's (CVS) Q2 Earnings?
by Zacks Equity Research
Akin to the previous quarters, net new business and the steady uptake of Maintenance Choice programs are likely to bolster CVS Health's (CVS) PBM business in Q2.
Is a Beat in Store for Axon Enterprise's (AAXN) Q2 Earnings?
by Zacks Equity Research
Axon Enterprise's (AAXN) expanded product offerings and strong execution likely to drive Q2 performance.
Tenet Healthcare (THC) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Tenet Healthcare's (THC) second-quarter earnings are likely to suffer due to lower revenues.
Acer Shares Down on FDA's CRL for Genetic Disorder Treatment
by Zacks Equity Research
Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.
Opexa Therapeutics Enters Oversold Territory
by Zacks Equity Research
Opexa Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Top Ranked Momentum Stocks to Buy for November 23rd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 23rd:
Opexa Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Opexa Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Acer Therapeutics (ACER) Shares March Higher, Can It Continue?
by Zacks Equity Research
Investors certainly have to be happy with Acer Therapeutics Inc. (ACER) and its short term performance
Small Drugmakers Edging Out the Bigshots: 7 Stocks to Buy
by Kinjel Shah
Smaller drugmakers are having a relatively better year than their larger counterparts. Here are seven stocks to buy.
Why Opexa Therapeutics (ACER) Could Shock the Market Soon
by Zacks Equity Research
Although overlooked by the investors, Opexa Therapeutics (ACER) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.
Top Ranked Momentum Stocks to Buy for May 18th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 18th:
Will Segmental Revenues Aid Cooper's (COO) Q1 Earnings?
by Zacks Equity Research
CooperSurgical sales and broad product spectrum are key catalysts for Cooper's (COO) Q1 earnings. However, falling estimates of other segments are likely to mar prospects.